{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:08:14Z","timestamp":1790690894584,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,21]]},"DOI":"10.7759\/cureus.72016","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T13:24:51Z","timestamp":1729517091000},"source":"Crossref","is-referenced-by-count":3,"title":["Real-World Evidence of Dydrogesterone 20 mg and 30 mg SR Usage in Pregnancy"],"prefix":"10.7759","author":[{"given":"Madhubala","family":"Manickavasagam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gudibanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011039","article-title":"Key to life: physiological role and clinical implications of progesterone","volume":"22","author":"Nagy B","year":"2021","unstructured":"Nagy B, Szekeres-Barth\u00f3 J, Kov\u00e1cs GL, et al.. Key to life: physiological role and clinical implications of progesterone. Int J Mol Sci. 2021, 22:11039. 10.3390\/ijms222011039","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2007.00512.x","article-title":"Progesterone during pregnancy: endocrine-immune cross talk in mammalian species and the role of stress","volume":"58","author":"Arck P","year":"2007","unstructured":"Arck P, Hansen PJ, Mulac Jericevic B, Piccinni MP, Szekeres-Bartho J. Progesterone during pregnancy: endocrine-immune cross talk in mammalian species and the role of stress. Am J Reprod Immunol. 2007, 58:268-79. 10.1111\/j.1600-0897.2007.00512.x","journal-title":"Am J Reprod Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1291615","article-title":"The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility","volume":"33","author":"Czyzyk A","year":"2017","unstructured":"Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecol Endocrinol. 2017, 33:421-4. 10.1080\/09513590.2017.1291615","journal-title":"Gynecol Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2015.1121982","article-title":"Dydrogesterone use in early pregnancy","volume":"32","author":"Mirza FG","year":"2016","unstructured":"Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016, 32:97-106. 10.3109\/09513590.2015.1121982","journal-title":"Gynecol Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2009.10.011","article-title":"Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium","volume":"65 Suppl 1","author":"Schindler AE","year":"2009","unstructured":"Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009, 65 Suppl 1:S3-11. 10.1016\/j.maturitas.2009.10.011","journal-title":"Maturitas"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/children11040422","article-title":"Exploring progesterone deficiency in first-trimester miscarriage and the impact of hormone therapy on foetal development: a scoping review","volume":"11","author":"Bataa M","year":"2024","unstructured":"Bataa M, Abdelmessih E, Hanna F. Exploring progesterone deficiency in first-trimester miscarriage and the impact of hormone therapy on foetal development: a scoping review. Children (Basel). 2024, 11:422. 10.3390\/children11040422","journal-title":"Children (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2020.09.002","article-title":"Sporadic pregnancy loss and recurrent miscarriage","volume":"69","author":"Devall AJ","year":"2020","unstructured":"Devall AJ, Coomarasamy A. Sporadic pregnancy loss and recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol. 2020, 69:30-9. 10.1016\/j.bpobgyn.2020.09.002","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103388","article-title":"Understanding progestins: from basics to clinical applicability","volume":"12","author":"Garc\u00eda-S\u00e1enz M","year":"2023","unstructured":"Garc\u00eda-S\u00e1enz M, Ibarra-Salce R, Pozos-Varela FJ, et al.. Understanding progestins: from basics to clinical applicability. J Clin Med. 2023, 12:3388. 10.3390\/jcm12103388","journal-title":"J Clin Med"},{"key":"ref9","article-title":"Using progestins in clinical practice","volume":"62","author":"Apgar BS","year":"2000","unstructured":"Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000, 62:1839-46, 1849-50.","journal-title":"Am Fam Physician"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20241778","article-title":"Practice profile of Indian gynaecologists on the use of micronized progesterone and dydrogesterone in pregnancy and assisted reproductive technology cycles: progress survey","volume":"13","author":"Ingale K","year":"2024","unstructured":"Ingale K, Malhotra N, Deshmukh P, Dhonde D, Mehta S. Practice profile of Indian gynaecologists on the use of micronized progesterone and dydrogesterone in pregnancy and assisted reproductive technology cycles: progress survey. Int J Reprod Contracept Obstet Gynecol. 2024, 13:1805-11. 10.18203\/2320-1770.ijrcog20241778","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20213839","article-title":"Dydrogesterone usage pattern in India: a knowledge, attitude and practice survey among Indian gynaecologists","volume":"10","author":"Khanna G","year":"2021","unstructured":"Khanna G, Dabade M, Dutta S, Deshpande N, Mane G, Shah C, Deshmukh G. Dydrogesterone usage pattern in India: a knowledge, attitude and practice survey among Indian gynaecologists. Int J Reprod Contracept Obstet Gynecol. 2021, 10:3793. 10.18203\/2320-1770.ijrcog20213839","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex023","article-title":"A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization","volume":"32","author":"Tournaye H","year":"2017","unstructured":"Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017, 32:1019-27. 10.1093\/humrep\/dex023","journal-title":"Hum Reprod"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20241298","article-title":"A multicentre phase III study comparing efficacy and safety of novel extended-release versus conventional formulation of dydrogesterone in Indian patients with endometriosis","volume":"13","author":"Sasikala T","year":"2024","unstructured":"Sasikala T, Kushwaha S, Agarwal M, et al.. A multicentre phase III study comparing efficacy and safety of novel extended-release versus conventional formulation of dydrogesterone in Indian patients with endometriosis. Int J Reprod Contracept Obstet Gynecol. 2024, 13:1425-31. 10.18203\/2320-1770.ijrcog20241298","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.10.1512","article-title":"Impact of dosage frequency on patient compliance","volume":"20","author":"Paes AH","year":"1997","unstructured":"Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997, 20:1512-7. 10.2337\/diacare.20.10.1512","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0020-5","article-title":"Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism","volume":"6","author":"Lalibert\u00e9 F","year":"2013","unstructured":"Lalibert\u00e9 F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013, 6:213-24. 10.1007\/s40271-013-0020-5","journal-title":"Patient"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390200073014","article-title":"The effect of prescribed daily dose frequency on patient medication compliance","volume":"150","author":"Eisen SA","year":"1990","unstructured":"Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990, 150:1881-4. 10.1001\/archinte.1990.00390200073014","journal-title":"Arch Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2021.1908252","article-title":"Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey","volume":"37","author":"Stute P","year":"2021","unstructured":"Stute P. Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey. Gynecol Endocrinol. 2021, 37:683-8. 10.1080\/09513590.2021.1908252","journal-title":"Gynecol Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.61622\/rbgo\/2024AO18","article-title":"Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study","volume":"46","author":"Tank J","year":"2024","unstructured":"Tank J, Gupte S, Mahapatra PC, et al.. Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study. Rev Bras Ginecol Obstet. 2024, 46:18. 10.61622\/rbgo\/2024AO18","journal-title":"Rev Bras Ginecol Obstet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013792.pub2","article-title":"Progestogens for preventing miscarriage: a network meta-analysis","volume":"4","author":"Devall AJ","year":"2021","unstructured":"Devall AJ, Papadopoulou A, Podesek M, Haas DM, Price MJ, Coomarasamy A, Gallos ID. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021, 4:CD013792. 10.1002\/14651858.CD013792.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2024.02.034","article-title":"Research progress of dydrogesterone in the treatment of endometriosis","volume":"296","author":"Tang W","year":"2024","unstructured":"Tang W, Zhu X, Bian L, Zhang B. Research progress of dydrogesterone in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2024, 296:120-5. 10.1016\/j.ejogrb.2024.02.034","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05900-z","article-title":"Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis","volume":"304","author":"Peng C","year":"2021","unstructured":"Peng C, Huang Y, Zhou Y. Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. Arch Gynecol Obstet. 2021, 304:231-52. 10.1007\/s00404-020-05900-z","journal-title":"Arch Gynecol Obstet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton AJ","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001, 23:1296-310. 10.1016\/S0149-2918(01)80109-0","journal-title":"Clin Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/301419-real-world-evidence-of-dydrogesterone-20-mg-and-30-mg-sr-usage-in-pregnancy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T13:24:53Z","timestamp":1729517093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/301419-real-world-evidence-of-dydrogesterone-20-mg-and-30-mg-sr-usage-in-pregnancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.72016","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}